Literature DB >> 24097857

Harnessing immune responses in the tumor microenvironment: all signals needed.

Dung T Le1, Elizabeth M Jaffee.   

Abstract

An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing of immunotherapies in combination with other established and targeted therapies. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24097857      PMCID： PMC3839670          DOI： 10.1158/1078-0432.CCR-13-2424

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

Review 3.  Human correlates of provocative questions in pancreatic pathology.

Authors:  Oliver G McDonald; Anirban Maitra; Ralph H Hruban
Journal:  Adv Anat Pathol       Date:  2012-11       Impact factor: 3.875

4.  Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.

Authors:  Richard E Royal; Catherine Levy; Keli Turner; Aarti Mathur; Marybeth Hughes; Udai S Kammula; Richard M Sherry; Suzanne L Topalian; James C Yang; Israel Lowy; Steven A Rosenberg
Journal:  J Immunother       Date:  2010-10       Impact factor: 4.456

5.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

Authors:  Thomas J Lynch; Igor Bondarenko; Alexander Luft; Piotr Serwatowski; Fabrice Barlesi; Raju Chacko; Martin Sebastian; Joel Neal; Haolan Lu; Jean-Marie Cuillerot; Martin Reck
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

6.  CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.

Authors:  Gregory L Beatty; Elena G Chiorean; Matthew P Fishman; Babak Saboury; Ursina R Teitelbaum; Weijing Sun; Richard D Huhn; Wenru Song; Dongguang Li; Leslie L Sharp; Drew A Torigian; Peter J O'Dwyer; Robert H Vonderheide
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

7.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 8.  CD40 immunotherapy for pancreatic cancer.

Authors:  Robert H Vonderheide; David L Bajor; Rafael Winograd; Rebecca A Evans; Lauren J Bayne; Gregory L Beatty
Journal:  Cancer Immunol Immunother       Date:  2013-04-16       Impact factor: 6.968

9.  A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.

Authors:  Gregory L Beatty; Drew A Torigian; E Gabriela Chiorean; Babak Saboury; Alex Brothers; Abass Alavi; Andrea B Troxel; Weijing Sun; Ursina R Teitelbaum; Robert H Vonderheide; Peter J O'Dwyer
Journal:  Clin Cancer Res       Date:  2013-08-27       Impact factor: 12.531

10.  Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.

Authors:  Dung T Le; Eric Lutz; Jennifer N Uram; Elizabeth A Sugar; Beth Onners; Sara Solt; Lei Zheng; Luis A Diaz; Ross C Donehower; Elizabeth M Jaffee; Daniel A Laheru
Journal:  J Immunother       Date:  2013-09       Impact factor: 4.456
View more
  7 in total

Review 1.  Pathological and molecular evaluation of pancreatic neoplasms.

Authors:  Arvind Rishi; Michael Goggins; Laura D Wood; Ralph H Hruban
Journal:  Semin Oncol       Date:  2014-12-09       Impact factor: 4.929

2.  Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer.

Authors:  Lei Miao; Jingjing Li; Qi Liu; Richard Feng; Manisit Das; C Michael Lin; Tyler J Goodwin; Oleksandra Dorosheva; Rihe Liu; Leaf Huang
Journal:  ACS Nano       Date:  2017-08-28       Impact factor: 15.881

Review 3.  Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer.

Authors:  Darshil T Jhaveri; Lei Zheng; Elizabeth M Jaffee
Journal:  Semin Oncol       Date:  2014-07-22       Impact factor: 4.929

Review 4.  Molecular therapeutics in pancreas cancer.

Authors:  Vignesh Narayanan; Colin D Weekes
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

Review 5.  Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.

Authors:  Daniel V T Catenacci
Journal:  Mol Oncol       Date:  2014-10-18       Impact factor: 6.603

Review 6.  Potential of mRNA vaccines to become versatile cancer vaccines.

Authors:  Shiu-Ying Tsao
Journal:  World J Clin Oncol       Date:  2022-08-24

7.  T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.

Authors:  Alexander C Hopkins; Mark Yarchoan; Jennifer N Durham; Erik C Yusko; Julie A Rytlewski; Harlan S Robins; Daniel A Laheru; Dung T Le; Eric R Lutz; Elizabeth M Jaffee
Journal:  JCI Insight       Date:  2018-07-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.